Biocurex Updates Its Shareholders

BioCurex Inc. (OTCBB:BOCX), Richmond, British Columbia, a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics, has announced that CEO, Dr. Ricardo Moro, released a letter to shareholders. The letter serves to update Shareholders on the current events at BioCurex and the company's plans for the future. In the past few months, we have converted our canine RECAF tests to work with a synthetic peptide and we can say conclusively that it performs better than the previous antibody-based test. We have also been working on ways to preserve canine serum samples at room temperature for 10 to 14 days without affecting their RECAF test value. This is of paramount commercial relevance because veterinarians anywhere in North America could then send us the samples to test by regular mail at a fraction of the cost of shipping them frozen (in some locations, the cost of shipping frozen samples is higher than the cost of the test). It goes without saying that this innovation is very relevant to distributors in the USA and Canada because it lowers the cost of the test for the veterinarian by about 50 percent without lowering margins for them or the company. By the same token, this will also help our future distributors in Europe and Asia. We have made significant progress in developing this technology, but research in an emerging field is unpredictable and thus time consuming. Yet, as the company works through the experimental options that will provide the most stable results, the value of the data and the knowledge acquired by BioCurex, the more valuable the underlying technology and future products should be to the marketplace. There are many examples like this one and it is difficult to keep our shareholders up to date on the weekly advances we make in all these fronts. Thus, rather than discussing them one by one we'll focus on the value of the company and its technology, because shareholders who see their value deteriorate tend to lose focus on the company's inherent value.